New Hampshire reports 18% increase in prescription drug monitoring program utilization

The Health and Human Services Oversight Committee of the New Hampshire Legislature convened on May 16, 2025, to discuss the annual report of the state's prescription drug monitoring program (PDMP). The meeting highlighted significant trends in prescription practices, particularly concerning stimulant and opioid medications, and the implications for public health.

Adam Birch, the program administrator, presented data indicating a notable 18% increase in the utilization of the PDMP by healthcare professionals over the past year. This rise is attributed to improvements in the system's accessibility, allowing providers to integrate PDMP queries directly into their electronic health records. Birch emphasized that while the number of healthcare professionals registered with the PDMP has remained stable, the increased usage reflects a growing commitment to responsible prescribing practices.

A key focus of the discussion was the rising trend in stimulant prescriptions, particularly among adults aged 30 and over. Birch explained that changes in diagnostic criteria for attention deficit hyperactivity disorder (ADHD) have led to more adults being diagnosed, paralleling trends seen in autism spectrum diagnoses. This shift, combined with targeted advertising and expanded telehealth services, has contributed to increased demand for stimulant medications. Birch noted that while the overall volume of stimulant prescriptions is rising, the amount prescribed to individual patients has not significantly increased, suggesting that the prescribing practices remain cautious.

In contrast, opioid prescriptions have seen a decline since 2017, although they appear to be plateauing. Birch reported a decrease in high-risk prescribing behaviors, which is encouraging in the context of the ongoing opioid crisis. The committee discussed the importance of maintaining vigilance in monitoring prescription practices to prevent misuse and ensure that patients receive necessary medications without falling into patterns of abuse.

The meeting also addressed concerns regarding patient privacy within the PDMP. Birch reassured committee members that robust measures are in place to protect patient information, including an audit trail for individuals accessing their records. This commitment to privacy is crucial as the state continues to enhance its monitoring capabilities.

In conclusion, the discussions at the Health and Human Services Oversight Committee meeting underscored the evolving landscape of prescription practices in New Hampshire. With the rise in stimulant prescriptions and the stabilization of opioid use, the PDMP plays a vital role in ensuring safe prescribing and protecting public health. The committee anticipates further developments as telehealth services expand and as they continue to monitor these trends closely.